Investment

Investment Highlights

  • LC101 development was completed and led by the inventor of the branded Doxil®
  • Signed strategic agreement with tier 1 pharma company to commercialize LC101 in the U.S. market
  • Obtained FDA US marketing authorisation for LC101
  • FDA accredited, cGMP manufacturing facility secured to support commercial launch
  • Overall $500m ww market opportunity with very few competitors due to high entry barriers
    (i.e. complex nano-drug)

Upcoming Catalysts

  • LC101 obtained FDA US marketing authorisation
  • Further international expansion (e.g. China) of LC101 via on-going BD efforts
  • Pipeline of Liposomal products based on Ayana’s platform technology are in development
error: Content is protected !!